Compare ARK Genomic Revolution ETF (ARKG) vs Philip Morris International Inc. (PM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ARK Genomic Revolution ETF vs Philip Morris International Inc. — how do they compare? ARK Genomic Revolution ETF trades at $41.24, while Philip Morris International Inc. trades at $182.44 (market cap $283.07B). The key difference: Philip Morris International Inc. pays a 3.24% dividend while ARK Genomic Revolution ETF pays none. Which is the better fit depends on your goals.
| ARKG | PM | |
|---|---|---|
Sector | Sector/Thematic | Consumer Staples |
52-Week High | $43.57 | $191.86 |
52-Week Low | $23.09 | $144.33 |
Market Cap | — | $283.07B |
Enterprise Value | — | $329.56B |
Dividend Yield | — | 3.24% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ARKG trades at $41.32, down 3.91% today, with a bullish technical signal driven by moving averages. Recent news highlights biotech ETF strength in June 2026, fueled by strong earnings, M&A activity, and AI-driven drug discovery optimism. Key support lies at $40, with resistance at $44.
The outlook remains positive given sector tailwinds, but risks include regulatory hurdles and market volatility. Investor sentiment is buoyed by industry growth catalysts, though selective investment approaches are noted by analysts.
Philip Morris International (PM) trades at $181.62, up 0.25% on the day, with a bullish technical signal and strong analyst support. Recent earnings beat expectations in Q1 2026, and the company maintains robust profitability with a 26.74% net income margin. However, a recent $500 million impairment charge and lowered profit guidance due to cost pressures and currency swings present near-term headwinds. The stock is near the analyst consensus price target of $194, with support at $179 and resistance at $185.
The outlook for PM is cautiously optimistic, driven by its strong brand portfolio, including IQOS, and consistent cash flow generation. Investment opportunities lie in its dividend yield and potential for margin recovery. Key risks include regulatory challenges, illicit market growth in Europe, and ongoing cost inflation. Analyst consensus remains bullish, but investors should monitor execution against revised guidance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ARK Genomic Revolution ETF
ARKG is an actively managed ETF that invests in the genomic revolution. It focuses on companies leading in gene editing, CRISPR technology, therapeutics, and molecular diagnostics, including firms like CRISPR Therapeutics and Tempus AI.
Read more on ARKG →About Philip Morris International Inc.
Philip Morris International is an international tobacco company with a product portfolio primarily consisting of cigarettes and reduced-risk products, including heat-not-burn, vapor and oral nicotine products, which are sold in markets outside the United States. The company diversified away from nicotine products with the acquisition of Vectura, a provider of innovative inhaled drug delivery solutions, in 2021.
Read more on PM →
